Original Article

You have full text access to this OnlineOpen article

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype†

A population-based study from the California cancer Registry

  1. Katrina R. Bauer MS CTR1,‡,*,
  2. Monica Brown PhD2,
  3. Rosemary D. Cress DrPH1,3,
  4. Carol A. Parise PhD4,
  5. Vincent Caggiano MD4,5

Article first published online: 26 MAR 2007

DOI: 10.1002/cncr.22618

Issue

Cancer

Cancer

Volume 109, Issue 9, pages 1721–1728, 1 May 2007

Additional Information

How to Cite

Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. and Caggiano, V. (2007), Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer, 109: 1721–1728. doi: 10.1002/cncr.22618

Author Information

  1. 1

    Public Health Institute/California Cancer Registry, Sacramento, California

  2. 2

    Public Health Institute/Cancer Surveillance Program, Sacramento, California

  3. 3

    Department of Health Sciences, Division of Epidemiology, UC Davis, California

  4. 4

    Sutter Institute for Medical Research, Sacramento, California

  5. 5

    Sutter Cancer Center/Cancer Surveillance Program, Sacramento, California

  1. ‡

    Fax: (916) 779-2608

*Research Associate IV, California Cancer Registry, Public Health Institute, 1700 Tribute Rd. Ste. 100, Sacramento, CA 95815-4402

  1. †

    The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Health Services, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred.

Publication History

  1. Issue published online: 18 APR 2007
  2. Article first published online: 26 MAR 2007
  3. Manuscript Accepted: 23 JAN 2007
  4. Manuscript Revised: 7 DEC 2006
  5. Manuscript Received: 26 SEP 2006

Funded by

  • California Department of Health Services
  • California Health and Safety Code Section. Grant Number: 103885
  • National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Grant Number: N01-PC-35136
  • Northern California Cancer Center. Grant Number: N01-PC-35139
  • University of Southern California. Grant Number: N02-PC-15105
  • Public Health Institute
  • Centers for Disease Control
  • Prevention's National Program of Cancer Registries. Grant Number: U55/CCR921930-02
  • Public Health Institute

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (147K)

REFERENCES

  • 1
    American Cancer Society. California Facts and Figures 2006. Oakland, CA: California Division and Public Health Institute, California Cancer Registry; 2005.
  • 2
    Campleman S, Curtis R. Demographic aspects of breast cancer incidence and mortality in California, 1988–1999. In: MorrisC, KwongSL, eds. Breast Cancer in California, 2003 Sacramento, CA: California Department of Health Services, Cancer Surveillance Section, July 2004.
  • 3
    Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer. 2003; 97: 2853–2860.
    Direct Link:
  • 4
    Polite BN, Olopade OI. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl ): S166–175.
  • 5
    Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005; 97: 439–448.
  • 6
    Cunningham JE, Butler WM. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat. 2004; 88: 161–176.
  • 7
    Newman LA. Breast cancer in African-American women. Oncologist. 2005; 10: 1–14.
  • 8
    Ries L, Eisner M, Kosary M. SEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer Institute, 2003.
  • 9
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747–752.
  • 10
    Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 8418–8423.
  • 11
    Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869–10874.
  • 12
    Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003; 95: 1482–1485.
  • 13
    Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19: 264–271.
  • 14
    Kandel MJ, Stadler Z, Masciari S, et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol (Meeting Abstracts). 2006; 24(18 Suppl ): 508.
  • 15
    Cancer Reporting in California: Abstracting and Coding Procedures for Hospitals. California Cancer Reporting System Standards. Vol. I. Sacramento, CA: California Department of Health Services, Cancer Surveillance Section, 2006.
  • 16
    Fritz AG. International classification of diseases for oncology: ICD-O. 3rd ed. Geneva: World Health Organization; 2000.
  • 17
    Fritz A. Recording tumor markers in collaborative staging system site-specific factors. Available from URL: http://www.cancerstaging.org/cstage/tumormarkers.pdf Accessed April on 28, 2006.
  • 18
    DAKO HERCEPTest Information Web site. Summary of Procedure, Vol. 2006, October 15, 2003. Available from URL: http://www.herceptin.com/herceptin/professional/testing/faqs.jsp Accessed on June 7, 2006.
  • 19
    PathVysion. HER-2 DNA probe kit package insert. Vysis, Downers Grove, CA, February, 2002.
  • 20
    Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001; 12: 703–711.
  • 21
    Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
  • 22
    SEER Extent of Disease 1998, Codes and Coding Instructions. 3rd ed. Bethesda, MD: National Cancer Institute, National Institutes of Health; 1998.
  • 23
    Seiffert JE, National Cancer Institute (U.S.). SEER Program: Comparative Staging Guide for Cancer. Bethesda, MD: U.S. Dept. of Health and Human Services Public Health Service National Institutes of Health National Cancer Institute, 1993.
  • 24
    Fleiss JL, Levin BA, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed. Hoboken, NJ: Wiley-Interscience; 2003.
  • 25
    Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993; 329: 326–331.
  • 26
    Breen N, Wesley MN, Merrill RM, Johnson K. The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. Ethn Dis. 1999; 9: 111.
  • 27
    McWhorter WP, Mayer WJ. Black/white differences in type of initial breast cancer treatment and implications for survival. Am J Public Health. 1987; 77: 1515–1517.
  • 28
    Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002; 94: 490–496.
  • 29
    Gordon NH. Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev. 2003; 22: 55–65.
  • 30
    Field TS, Buist DS, Doubeni C, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005: 88–95.
  • 31
    Jatoi I, Becher H, Leake CR. Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system. Cancer. 2003; 98: 894–899.
    Direct Link:
  • 32
    Wojcik BE, Spinks MK, Optenberg SA. Breast carcinoma survival analysis for African American and white women in an equal-access health care system. Cancer. 1998; 82: 1310–1318.
    Direct Link:
  • 33
    Albain KS, Unger J, Hutchins LF. Outcome of African Americans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials. San Antonio Breast Cancer Symposium 2003: 21.
  • 34
    Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer. 2000; 88: 114–123.
    Direct Link:
  • 35
    Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006; 24: 1342–1349.
  • 36
    Newman LA, Mason J, Cote D, et al. African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 white American patients with carcinoma of the breast. Cancer. 2002; 94: 2844–2854.
    Direct Link:
  • 37
    Aziz H, Hussain F, Sohn C, et al. Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol. 1999; 22: 436–440.
  • 38
    Furberg H, Millikan R, Dressler L, Newman B, Geradts J. Tumor characteristics in African American and white women. Breast Cancer Res Treat. 2001; 68: 33–43.
  • 39
    Henson DE, Chu KC, Levine PH. Histologic grade, stage, and survival in breast carcinoma: comparison of African American and Caucasian women. Cancer. 2003; 98: 908–917.
    Direct Link:
  • 40
    Jones BA, Kasl SV, Howe CL, et al. African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer. 2004; 101: 1293–1301.
    Direct Link:
  • 41
    Newman LA, Alfonso AE. Age-related differences in breast cancer stage at diagnosis between black and white patients in an urban community hospital. Ann Surg Oncol. 1997; 4: 655–662.
  • 42
    Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003; 97: 134–147.
    Direct Link:
  • 43
    Carey LA, Perou CM, Dressler LG, et al. Race and the poor prognosis basal breast tumor (BBT) phenotype in the population-based Carolina Breast Cancer Study (CBCS). J Clin Oncol (Meeting Abstracts). 2004; 22(14 Suppl ): 9510.
  • 44
    Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492–2502.
  • 45
    Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367–5374.
  • 46
    Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006; 12: 1533–1539.
View Full Article (HTML) Get PDF (147K)